Shares of Glenmark gained 10% to Rs 2,094 on July 11, making it a top gainer on the Nifty Midcap 150 index. Mankind Pharma, NMDC, Gland, and Alkem Lab were also among the top gainers. Moneycontrol ...

Glenmark Share Price: Shares of Glenmark Pharmaceuticals Ltd surged 10 per cent in early trade on Friday, scaling a new ...

Glenmark Pharma shares surged by 10% to hit the upper circuit level in early trade, reaching Rs 2094.40. This significant ...

In Friday’s market session, top Indian corporates like Tata Consultancy Services (TCS), Hindustan Unilever Ltd (HUL), Bharat Forge, and Glenmark Pharma found themselves in focus as global brokerages ...

ASX health stocks fall o.92% over past five days as US President Donald Trump renews threat to impose tariffs on pharmaceutical imports.

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

Dividend investing, like most things in life, can be rewarding if done correctly or a headache if you make crucial mistakes. The key to dividend investing is to pick the right typ ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...

AbbVie (ABBV) closed the most recent trading day at $195.00, moving +2.3% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.28%. On the other hand, the Dow registered ...

AbbVie Inc. (NYSE:ABBV) saw its stock jump 3.4% after announcing a major licensing agreement with IGI Therapeutics, securing ...

AbbVie’s projected 2025 earnings just got trimmed by Cantor Fitzgerald, slicing estimates from $12.31 per share to $11.84.